Kura Oncology DEF 14A: Executive Compensation Details
Ticker: KURA · Form: DEF 14A · Filed: Apr 11, 2025 · CIK: 1422143
| Field | Detail |
|---|---|
| Company | Kura Oncology, INC. (KURA) |
| Form Type | DEF 14A |
| Filed Date | Apr 11, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: def-14a, executive-compensation, equity-awards
TL;DR
Kura Oncology's DEF 14A is out, detailing exec pay & equity awards for 2024. Focus on compensation structure.
AI Summary
Kura Oncology, Inc. filed a DEF 14A on April 11, 2025, for the fiscal year ending December 31, 2024. The filing details executive compensation, including equity awards granted and vested during the year. Key figures relate to the change in fair value of outstanding equity awards for non-personnel members and the fair value of equity awards granted to executive personnel.
Why It Matters
This filing provides transparency into how Kura Oncology compensates its top executives, which can influence investor perception and employee morale.
Risk Assessment
Risk Level: low — This is a routine annual filing (DEF 14A) that primarily discloses executive compensation details and does not contain new material financial information or strategic shifts.
Key Numbers
- 2024 — Fiscal Year (Reporting period for executive compensation details.)
- 2021-2024 — Equity Award Periods (Covers historical and current equity award data for executive compensation.)
Key Players & Entities
- Kura Oncology, Inc. (company) — Filer
- 20250411 (date) — Filing Date
- 20250605 (date) — Period of Report
- 1231 (date) — Fiscal Year End
- ZETA ACQUISITION CORP III (company) — Former Company Name
FAQ
What is the primary purpose of this DEF 14A filing?
The primary purpose of this DEF 14A filing is to provide detailed information regarding Kura Oncology, Inc.'s executive compensation, director compensation, and corporate governance matters for the fiscal year ending December 31, 2024.
When was this DEF 14A filing submitted to the SEC?
This DEF 14A filing was submitted to the SEC on April 11, 2025.
What is Kura Oncology's fiscal year end date?
Kura Oncology's fiscal year end date is December 31.
What type of compensation is detailed in the summary compensation table for the applicable year?
The summary compensation table for the applicable year details equity awards granted to executive personnel, including their change in fair value and vesting dates.
What was Kura Oncology's former company name?
Kura Oncology, Inc.'s former company name was ZETA ACQUISITION CORP III, with a date of name change on December 27, 2007.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 11, 2025 regarding Kura Oncology, Inc. (KURA).